Duchenne Muscular Dystrophy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Duchenne Muscular Dystrophy remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 196 matched trial records and 268 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07682129 | ENTR-601-45 + ENTR-601-44 | Phase 2; Not yet recruiting | Entrada Therapeutics, Inc. | Netherlands, Belgium, United Kingdom, Italy, Spain | Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period) (From baseline through End of Study (up to 2 years).) | 2032-03-01 |
| NCT07674758 | Intervention not normalized | Not Applicable; Recruiting | Vanderbilt University Medical Center | United States | Mortality (baseline to 10 years) | 2029-02-01 |
| NCT07673809 | GNR-097 | Phase 1/2; Recruiting | Generium ZAO | Belarus, Russia | Number and percentage of participants with treatment-emergent adverse events (AEs), AEs of special interest and serious adverse events (SAEs) (Baseline to End of Study (Week 104)) | 2029-08-02 |
| NCT07664124 | Intervention not normalized | Not Applicable; Not yet recruiting | Centre Hospitalier Universitaire de Liege | Belgium | Device usage (recording time) (Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24); Patient compliance (Min) (Recording periods at Baseline, Month 6, Month 12, Month 18, Month 24) | 2029-06-30 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- Vamorolone for Duchenne Muscular Dystrophy (Phase 2): the indexed record reports TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028).
- Lowering pre-existing immunity to adeno-associated virus-based gene therapy: Pre treatment with imlifidase or plasmapheresis prior to administration of delandistrogene moxeparvovec in Duchenne muscular dystrophy ‑ (Phase 1): the indexed record reports Micro-dystrophin Expression(Week 12) = 21.5 % ( 0.96 - 42.03); Micro-dystrophin Expression(Week 12) = 1.72 % ( 1.46 - 2.11).
- Family experience data with delandistrogene moxeparvovec gene therapy treatment for Duchenne muscular dystrophy. (Not Applicable): the indexed record reports Improvement in at least one of the most impactful symptoms = 96.0 %.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including ENTR-601-45 (Phase 1/2; DMD exon 45), ENTR-601-44 (Phase 1/2; DMD exon 44), GNR-097 (Phase 1/2). Company & Deal Intelligence records identify sponsor context for Entrada Therapeutics, Inc. (TRDA), Vanderbilt University Medical Center, Generium ZAO, Centre Hospitalier Universitaire de Liege. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Duchenne Muscular Dystrophy has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
